LY3298176

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Wed, 06/12/19 - 09:45 am
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
Endpoints
Thu, 10/4/18 - 11:58 am
Eli Lilly
diabetes
Novo Nordisk
Ozempic
LY3298176
Trulicity